News APP

NewsApp (Free)

Read news as it happens
Download NewsApp

Available on  gplay

This article was first published 4 years ago
Home  » News » India's first COVID-19 vaccine gets nod for human trials

India's first COVID-19 vaccine gets nod for human trials

Source: PTI   -  Edited By: Roshneesh Kmaneck
June 30, 2020 08:34 IST
Get Rediff News in your Inbox:

The country's 'first' indigenous COVID-19 vaccine COVAXIN, developed by Hyderabad-based Bharat Biotech in collaboration with Indian Council of Medical Research and National Institute of Virology, has got the nod for human clinical trials from the Drug Controller General of India, the company said on Monday.



The Phase I and Phase II clinical trials of the vaccine for SARS-CoV-2, approved after pre-clinical studies demonstrated safety and immune response, would start across the country next month.

 

The collaboration with ICMR and the NIV was instrumental in the development of the vaccine, the company said in a release.

The indigenous and inactivated vaccine has been developed at Bharat Biotechs BSL-3 (Bio-Safety Level 3) high containment facility located in the Genome Valley, a release said.

The Drug Controller General of India CDSCO (The Central Drugs Standard Control Organisation), Ministry of Health & Family Welfare granted permission to initiate Phase I & II Human clinical trials after the company submitted results generated from pre-clinical studies, demonstrating safety and immune response. Human clinical trials are scheduled to start across India in July 2020, the release said.

Chairman and Managing Director of the company Dr Krishna Ella said: We are proud to announce COVAXIN, Indias first indigenous vaccine against COVID-19. The collaboration with ICMR and NIV was instrumental in the development of this vaccine.

"The proactive support and guidance from CDSCO has enabled approvals to this project. Our R&D and manufacturing teams worked tirelessly to deploy our proprietary technologies towards this platform," he said.

Expedited through the national regulatory protocols, the company accelerated its objective in completing the comprehensive pre-clinical studies.

Results from these studies have been promising and show extensive safety and effective immune responses, the release added.

Besides Bharat Biotech, at least five other Indian companies are working on a vaccine for the deadly coronavirus while similar efforts are underway in different countries. 

Get Rediff News in your Inbox:
Source: PTI  -  Edited By: Roshneesh Kmaneck© Copyright 2024 PTI. All rights reserved. Republication or redistribution of PTI content, including by framing or similar means, is expressly prohibited without the prior written consent.